EGFR and non-small cell lung carcinoma: In NSCLC cells harboring drug-sensitive EGFR mutants, EGFR TKI (erlotinib or gefitinib) triggers intrinsic (mitochondrial) apoptosis pathway via rapid increase in BIM levels and consequently the activation of the pro-apoptotic pore-former, BAX [36–38].